Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin for cancer-related anorexia in small cell lung cancer
ACTRN12622000129785Phase 2Terminated
- Sponsor
- University of Technology Sydney
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anorexia nervosa (AN) comparing Anamorelin with Placebo (2 arms). Primary endpoints: Feasibility - recruitment rate, Desirability - signal for efficacy and 1 more. Started May 2023; status: terminated.
02
Drugs
anamorelin
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on ACTRN12622000129785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000129785.